These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide. Nauck MA; Mirna AEA; Quast DR Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380 [TBL] [Abstract][Full Text] [Related]
5. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Nauck MA; Quast DR; Wefers J; Pfeiffer AFH Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013 [TBL] [Abstract][Full Text] [Related]
6. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Nauck MA; D'Alessio DA Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763 [TBL] [Abstract][Full Text] [Related]
7. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Frías JP Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356 [TBL] [Abstract][Full Text] [Related]
8. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review. Mima A; Nomura A; Fujii T Biomed Pharmacother; 2023 Sep; 165():115032. PubMed ID: 37331253 [TBL] [Abstract][Full Text] [Related]
9. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes. Nowak M; Nowak W; Grzeszczak W Endokrynol Pol; 2022; 73(4):745-755. PubMed ID: 35593668 [TBL] [Abstract][Full Text] [Related]
10. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. Skow MA; Bergmann NC; Knop FK Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961 [TBL] [Abstract][Full Text] [Related]
11. Tirzepatide: A Review in Type 2 Diabetes. France NL; Syed YY Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874 [TBL] [Abstract][Full Text] [Related]
12. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097 [TBL] [Abstract][Full Text] [Related]
13. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691 [TBL] [Abstract][Full Text] [Related]
14. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795 [TBL] [Abstract][Full Text] [Related]
15. Structural determinants of dual incretin receptor agonism by tirzepatide. Sun B; Willard FS; Feng D; Alsina-Fernandez J; Chen Q; Vieth M; Ho JD; Showalter AD; Stutsman C; Ding L; Suter TM; Dunbar JD; Carpenter JW; Mohammed FA; Aihara E; Brown RA; Bueno AB; Emmerson PJ; Moyers JS; Kobilka TS; Coghlan MP; Kobilka BK; Sloop KW Proc Natl Acad Sci U S A; 2022 Mar; 119(13):e2116506119. PubMed ID: 35333651 [TBL] [Abstract][Full Text] [Related]
16. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931 [TBL] [Abstract][Full Text] [Related]
17. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes]. Scheen AJ; Radermecker RP; Paquot N Rev Med Suisse; 2022 Aug; 18(792):1539-1544. PubMed ID: 36004653 [TBL] [Abstract][Full Text] [Related]
18. Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP. Wang L Drug Des Devel Ther; 2022; 16():1547-1559. PubMed ID: 35651477 [TBL] [Abstract][Full Text] [Related]